Lineage Cell Therapeutics (LCTX) EBIT: 2010-2025
Historic EBIT for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.8 million.
- Lineage Cell Therapeutics' EBIT rose 1.41% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 54.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 13.16% up from last year.
- According to the latest figures from Q3 2025, Lineage Cell Therapeutics' EBIT is -$3.8 million, which was up 80.86% from -$19.8 million recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' EBIT peaked at -$3.8 million during Q3 2025, and registered a low of -$28.2 million during Q4 2021.
- Moreover, its 3-year median value for EBIT was -$6.4 million (2023), whereas its average is -$6.9 million.
- Per our database at Business Quant, Lineage Cell Therapeutics' EBIT tumbled by 380.07% in 2021 and then surged by 76.49% in 2022.
- Over the past 5 years, Lineage Cell Therapeutics' EBIT (Quarterly) stood at -$28.2 million in 2021, then spiked by 76.49% to -$6.6 million in 2022, then increased by 4.17% to -$6.4 million in 2023, then climbed by 19.68% to -$5.1 million in 2024, then climbed by 1.41% to -$3.8 million in 2025.
- Its EBIT was -$3.8 million in Q3 2025, compared to -$19.8 million in Q2 2025 and -$6.5 million in Q1 2025.